Predictive and prognostic markers are at the forefront of personalised cancer care, offering clinicians the ability to both anticipate a patient’s response to specific therapies and gauge the likely ...
Researchers in Japan have developed a predictive model that could improve treatment decisions for advanced pancreatic cancer patients. By combining tumor marker readings with patients' genetic ...
PITTSBURGH, March 25, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (POAI), a leader in AI-driven drug discovery, announced today that it has successfully developed predictive models derived from ...
DNA levels at baseline and during treatment predict response and progression free survival in advanced breast cancer, ...
Tumors are heterogenous masses of cells that rapidly divide. Many cells have different mutations, functions, and ways to avoid immune cell detection and drive tumor progression. The heterogeneity of ...
The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...
Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...
EON: Phase II trial of etigilimab (MPH313) in combination with nivolumab in patients with recurrent platinum-resistant clear cell ovarian cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...
A tumor marker for pancreatic cancer helps healthcare professionals detect, diagnose, or treat it. However, a person can have high tumor marker levels without having cancer. Tumor markers are ...
Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results